Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of … Read more
Crispr Therapeutics AG (CRSP) - Net Assets
Latest net assets as of December 2025: $1.92 Billion USD
Based on the latest financial reports, Crispr Therapeutics AG (CRSP) has net assets worth $1.92 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.27 Billion) and total liabilities ($343.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.92 Billion |
| % of Total Assets | 84.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -19.91% |
| 10-Year Change | 725.36% |
| Growth Volatility | 55.68 |
Crispr Therapeutics AG - Net Assets Trend (2014–2025)
This chart illustrates how Crispr Therapeutics AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Crispr Therapeutics AG (2014–2025)
The table below shows the annual net assets of Crispr Therapeutics AG from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.92 Billion | -0.53% |
| 2024-12-31 | $1.93 Billion | +2.62% |
| 2023-12-31 | $1.88 Billion | +0.39% |
| 2022-12-31 | $1.88 Billion | -21.84% |
| 2021-12-31 | $2.40 Billion | +44.18% |
| 2020-12-31 | $1.66 Billion | +77.15% |
| 2019-12-31 | $939.42 Million | +139.53% |
| 2018-12-31 | $392.19 Million | +108.80% |
| 2017-12-31 | $187.83 Million | -19.33% |
| 2016-12-31 | $232.85 Million | +899.50% |
| 2015-12-31 | $-29.12 Million | -317.61% |
| 2014-12-31 | $-6.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Crispr Therapeutics AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 193914800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.09 Million | 0.16% |
| Other Comprehensive Income | $4.82 Million | 0.25% |
| Other Components | $3.86 Billion | 200.93% |
| Total Equity | $1.92 Billion | 100.00% |
Crispr Therapeutics AG Competitors by Market Cap
The table below lists competitors of Crispr Therapeutics AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hoa Phat Group JSC
VN:HPG
|
$4.79 Billion |
|
Paylocity Holdng
NASDAQ:PCTY
|
$4.79 Billion |
|
China Natl Chem Engineering Co
SHG:601117
|
$4.80 Billion |
|
Marico Limited
NSE:MARICO
|
$4.80 Billion |
|
Atour Lifestyle Holdings Limited American Depositary Shares
NASDAQ:ATAT
|
$4.79 Billion |
|
Telefônica Brasil S.A.
SA:VIVT3
|
$4.78 Billion |
|
Primo Brands Corporation
NYSE:PRMB
|
$4.77 Billion |
|
COM.INTL BK GDR S LE 10
F:CIN
|
$4.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Crispr Therapeutics AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,932,080,000 to 1,921,813,000, a change of -10,267,000 (-0.5%).
- Net loss of 581,599,000 reduced equity.
- Share repurchases of 71,253,000 reduced equity.
- New share issuances of 398,090,000 increased equity.
- Other comprehensive income increased equity by 2,981,000.
- Other factors increased equity by 241,514,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-581.60 Million | -30.26% |
| Share Repurchases | $71.25 Million | -3.71% |
| Share Issuances | $398.09 Million | +20.71% |
| Other Comprehensive Income | $2.98 Million | +0.16% |
| Other Changes | $241.51 Million | +12.57% |
| Total Change | $- | -0.53% |
Book Value vs Market Value Analysis
This analysis compares Crispr Therapeutics AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-0.24 | $50.09 | x |
| 2015-12-31 | $-0.99 | $50.09 | x |
| 2016-12-31 | $19.00 | $50.09 | x |
| 2017-12-31 | $4.69 | $50.09 | x |
| 2018-12-31 | $8.18 | $50.09 | x |
| 2019-12-31 | $16.50 | $50.09 | x |
| 2020-12-31 | $25.23 | $50.09 | x |
| 2021-12-31 | $29.85 | $50.09 | x |
| 2022-12-31 | $24.12 | $50.09 | x |
| 2023-12-31 | $23.77 | $50.09 | x |
| 2024-12-31 | $22.90 | $50.09 | x |
| 2025-12-31 | $21.37 | $50.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Crispr Therapeutics AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16569.77%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-30.26%) is below the historical average (-14.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.09 Million |
| 2015 | 0.00% | -10456.68% | 0.00x | 0.00x | $-22.92 Million |
| 2016 | -9.96% | -449.30% | 0.01x | 1.48x | $-46.49 Million |
| 2017 | -36.39% | -166.74% | 0.15x | 1.44x | $-87.14 Million |
| 2018 | -42.07% | -5281.08% | 0.01x | 1.25x | $-204.20 Million |
| 2019 | 7.12% | 23.09% | 0.27x | 1.14x | $-27.08 Million |
| 2020 | -20.96% | -48520.86% | 0.00x | 1.10x | $-515.29 Million |
| 2021 | 15.74% | 41.36% | 0.33x | 1.15x | $137.72 Million |
| 2022 | -34.67% | -149122.71% | 0.00x | 1.20x | $-837.72 Million |
| 2023 | -8.16% | -41.52% | 0.17x | 1.18x | $-341.89 Million |
| 2024 | -18.96% | -1046.43% | 0.02x | 1.16x | $-559.46 Million |
| 2025 | -30.26% | -16569.77% | 0.00x | 1.18x | $-773.78 Million |
Industry Comparison
This section compares Crispr Therapeutics AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Crispr Therapeutics AG (CRSP) | $1.92 Billion | 0.00% | 0.18x | $4.79 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |